A novel synthetic crystalline material, EMM-28, can be synthesized in the presence of an organic structure directing agent (Q) selected from one or more of the following dications:

##STR00001##

EMM-28 may be used in organic compound conversion reactions and sorptive processes.

A quinone derivative with a high redox potential that does not undergo Michael addition or proto-desulfonation. This molecule addresses the key issues faced with the positive side material of an aqueous all-organic flow battery. This new molecule is 2,5-dihydroxy-4,6-dimethylbenzene-1,3-disulfonic acid (or the disulfonate salt thereof). This quinone derivative offers good solubility, electrochemical reversibility, and robustness to charge/discharge cycling. Quinones with reduced crossover are also provided.

A quinone derivative with a high redox potential that does not undergo Michael addition or proto-desulfonation. This molecule addresses the key issues faced with the positive side material of an aqueous all-organic flow battery. This new molecule is 2,5-dihydroxy-4,6-dimethylbenzene-1,3-disulfonic acid (or the disulfonate salt thereof). This quinone derivative offers good solubility, electrochemical reversibility, and robustness to charge/discharge cycling. Quinones with reduced crossover are also provided.

A novel synthetic crystalline material, EMM-28, can be synthesized in the presence of an organic structure directing agent (Q) selected from one or more of the following dications: ##STR00001##
EMM-28 may be used in organic compound conversion reactions and sorptive processes.

A novel synthetic crystalline material, EMM-28, can be synthesized in the presence of an organic structure directing agent (Q) selected from one or more of the following dications: ##STR00001##
EMM-28 may be used in organic compound conversion reactions and sorptive processes.

Compounds of formula (I) having 1-sulfonamido-4-aryloxy as a basic backbone. A preliminary activity test showed that the compounds provide excellent interference of a binding of Nrf2 by Keap1, thereby activating Nrf2. The compounds have a potential anti-inflammatory activity and can be used to treat a plurality of inflammation-associated diseases, including chronic obstructive pulmonary disease (COPD), Alzheimer's disease, Parkinson's disease, atherosclerosis, chronic kidney disease (CKD), diabetes, gastroenteritis, rheumatoid arthritis, and the like.

##STR00001##

Compounds of formula (I) having 1-sulfonamido-4-aryloxy as a basic backbone. A preliminary activity test showed that the compounds provide excellent interference of a binding of Nrf2 by Keap1, thereby activating Nrf2. The compounds have a potential anti-inflammatory activity and can be used to treat a plurality of inflammation-associated diseases, including chronic obstructive pulmonary disease (COPD), Alzheimer's disease, Parkinson's disease, atherosclerosis, chronic kidney disease (CKD), diabetes, gastroenteritis, rheumatoid arthritis, and the like.

##STR00001##

In one aspect, there is provided a method of coupling an aromatic or vinylic compound having a fluorosulfonate substituent to a boron-containing compound. In another aspect, there is provided a method of coupling an aromatic or vinylic compound having a hydroxyl substituent to a boron-containing compound in a one-pot reaction.

A process for producing 3,5-di-tert-butylbenzenesulfonic acid includes forming a solution of 1,3,5-tri-tert-butyl benzene in a solvent, exposing said solution to anhydrous hydrogen chloride gas, and reacting 1,3,5-tri-tert-butylbenzene with a sulfonating agent to form 3,5-di-tert-butylbenzenesulfonic acid. Said exposing of said solution to anhydrous hydrogen chloride gas is carried out before reacting said 1,3,5-tri-tert-butylbenzene with said sulfonating agent. The process also includes recovering said 3,5-di-tert-butylbenzenesulfonic acid.

A process for producing 3,5-di-tert-butylbenzenesulfonic acid includes forming a solution of 1,3,5-tri-tert-butyl benzene in a solvent, exposing said solution to anhydrous hydrogen chloride gas, and reacting 1,3,5-tri-tert-butylbenzene with a sulfonating agent to form 3,5-di-tert-butylbenzenesulfonic acid. Said exposing of said solution to anhydrous hydrogen chloride gas is carried out before reacting said 1,3,5-tri-tert-butylbenzene with said sulfonating agent. The process also includes recovering said 3,5-di-tert-butylbenzenesulfonic acid.